Glioma – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s glioma forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with glioma per year?
- Of all people diagnosed with glioma, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of glioma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 15 glioma patient populations, including the following:
- Diagnosed incident cases of glioma.
- Diagnosed incident cases of astrocytic glioma.
- Diagnosed incident cases of oligodendroglioma and oligoastrocytoma.
- Diagnosed incident cases of oligodendroglioma.
- Diagnosed incident cases of oligoastrocytoma.
- Diagnosed incident cases of ependymal.
- Diagnosed incident cases of transformed glioblastoma.
- Diagnosed prevalent cases of astrocytic glioma.
- Diagnosed first-line drug-treatable glioblastoma.
Note: Coverage may vary by country.
Table of contents
- Glioma - Epidemiology - Emerging Markets
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of glioma)
- Diagnosed incident cases
- Grade distribution
- Diagnosed cases of transformed glioblastoma glioma
- Diagnosed prevalent cases
- Drug-treatable populations
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations
Katie Myatt, M.S., Senior Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Myatt worked as an epidemiologist for local and state public health departments performing infectious disease surveillance, both endemic and epidemic. Her interests are infectious disease epidemiology and cancer epidemiology. She received both her master’s degree in epidemiology and her bachelor’s degree in biology from the University of Louisville in Kentucky.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.